Can margituximab be used in combination with immunotherapy (such as PD-1)?

Margetuximab (margetuximab-cmkb) is a new generation of HER2-targeting monoclonal antibody. The Fc segment is structurally optimized to enhance the binding ability to Fcγ receptor IIIa (CD16A), thus improving the antibody-dependent cell-mediated cytotoxicity (ADCC) effect. Compared with traditional trastuzumab, margetuximab can more effectively activate the immune clearance ability of natural killer cells (NK cells) against HER2-positive tumors. With the widespread application of immunotherapy in solid tumors, researchers have begun to explore the possibility of combining margituximab with immune checkpoint inhibitors (such as PD-1/PD-L1 inhibitors) to enhance anti-tumor immune responses.

Theoretically, the combination of margituximab andPD-1 inhibitors has synergistic potential. Margetuximab is expected to improve the immune "cold" state in the tumor microenvironment by increasing tumor antigen presentation and stimulating NK cell activity. PD-1/PD-L1 inhibitors can relieve the inhibition of T cell function and activate cytotoxic T cells to further attack tumor cells. The combination of the two may stimulate a broader immune response, especially in tumors with both HER2 expression and an immunosuppressive microenvironment, such as some patients with HER2-positive breast cancer.

There are already early studies and clinical trials exploring the feasibility of combining margetuximab with immune checkpoint inhibitors. For example, some phase I/II trials are evaluating its effectiveness in combination with PD-1 antibodies such as pembrolizumab in patients with HER2-positive advanced breast cancer. Although the results are still exploratory, preliminary data suggest that some patients may achieve longer-lasting disease control and immune activation profiles. Importantly, the safety of this combination therapy is also continuing to be evaluated, and no significant additive immune-related toxicities have been identified.

Reference materials:https://www.margenza.com/